Last reviewed · How we verify
XRD-0394
At a glance
| Generic name | XRD-0394 |
|---|---|
| Sponsor | XRad Therapeutics Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Concurrent XRD-0394 With Radiation Therapy for High Grade Gliomas (EARLY_PHASE1)
- Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- XRD-0394 CI brief — competitive landscape report
- XRD-0394 updates RSS · CI watch RSS
- XRad Therapeutics Inc portfolio CI